Programmaleider Zorg en Participatie bij Chronische aandoeningen; bijzonder hoogleraar 'Farmaceutisch zorgonderzoek', Rijksuniversiteit Groningen
Publicatie
Publicatie datum
Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib.
Florentinus, S.R., Nielsen, M.W., Dijk, L. van, Leufkens, H.G.M., Hansen, E.H., Heerdink, E.R. Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. European Journal of Clinical Pharmacology: 2005, 61, p. 157-159.
Download de PDF
Objective: To identify socio-demographic characteristics of the first patients receiving a new drug-rofecoxib. Outcome measurement: Patients starting on rofecoxib or another non-steroidal anti-inflammatory drug (NSAID) and who had not received any NSAIDs the 90 days prior to starting. Results: Starting on rofecoxib was associated with an increasing age (OR in age 80 years and older 8.7; 95% CI 6.7–11.2), a poor self-perceived health (OR=2.4; 95% CI 1.8–3.3), female gender (OR=1.4; 95% CI 1.2–1.6), private insurance (OR=1.3; 1.1–1.5) and previous acetaminophen use (OR=1.3; 1.1–1.7). Conclusion: This study noted that specific patient characteristics were associated with getting rofecoxib prescribed shortly after marketing. General practitioners should be aware of selectively prescribing new drugs to specific patients because it may place patients at unintentional and avoidable risk. (aut. ref.)
Objective: To identify socio-demographic characteristics of the first patients receiving a new drug-rofecoxib. Outcome measurement: Patients starting on rofecoxib or another non-steroidal anti-inflammatory drug (NSAID) and who had not received any NSAIDs the 90 days prior to starting. Results: Starting on rofecoxib was associated with an increasing age (OR in age 80 years and older 8.7; 95% CI 6.7–11.2), a poor self-perceived health (OR=2.4; 95% CI 1.8–3.3), female gender (OR=1.4; 95% CI 1.2–1.6), private insurance (OR=1.3; 1.1–1.5) and previous acetaminophen use (OR=1.3; 1.1–1.7). Conclusion: This study noted that specific patient characteristics were associated with getting rofecoxib prescribed shortly after marketing. General practitioners should be aware of selectively prescribing new drugs to specific patients because it may place patients at unintentional and avoidable risk. (aut. ref.)
Gegevensverzameling